Regeneron acquired 23andMe for $256M, gaining 15M DNA profiles to enhance R&D. Find out why REGN stock is a Buy.

DB-OTO, which Regeneron obtained from the 2023 acquisition of Decibel Therapeutics for $109 million, works by delivering a ...

With pricing reforms and PBM overhauls looming, pharma investors need to differentiate between companies that can absorb ...

Me gene privacy question takes a turn in bankruptcy Why a big AI player wants a quarter-million bucks from 23andMe Why a big ...

Biotechnology company Regeneron Pharmaceuticals is buying 23andMe for $256 million, two months after the genetic testing ...

Being spliced on to Regeneron will free the genetic testing company from its fatal dependence on sporadic revenue ...

Regeneron said Monday it will "prioritize the privacy, security and ethical use" of the personal DNA data from about 15 million people in a $256 million deal to acquire assets of bankrupt 23andMe ...

Regeneron (REGN) stock was upgraded to Buy and AbbVie (ABBV) stock was downgraded at Citi based on policy risks under Trump's drug reforms. Read more here.

Regeneron Pharmaceuticals discovers ... The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases ...